Evidence-based educational resources for healthcare providers on cancer genomic topics.
Hereditary Breast and Ovarian Cancer
Point of care tool: A two-part (I, II) tool to identify individuals likely to benefit from a genomic risk assessment (I) and those predicted to be at increased risk to carry a mutation in the BRCA1 or BRCA2 genes (II). (April 2025)
GECKO on the run: A 4-page, evidence-based summary for healthcare providers. Features a bottom line, red flags for a genomic assessment, associated cancer risk, benefits and limitations of genetic testing. (October 2023)
GECKO deep dive: A 16-page, comprehensive evidence-based resource for healthcare providers. Features a bottom line, red flags for a genomic assessment, associated cancer risk, benefits and limitations of genetic testing, references and more. (September 2023)
Lynch Syndrome (Hereditary colorectal and endometrial cancer)
Point of care tool: A two-part (I, II) tool containing three questions to stratify an individual’s risk for hereditary colorectal, endometiral and other cancers and to identify those that likely to benefit from a genomic assessment (I), as well as those at high risk to carry a mutation in a Lynch syndrome gene (II). (January 2023)
GECKO on the run: A 3-page, evidence-based summary for healthcare practitioners. Features a bottom line, red flags for a genomic assessment, associated cancer risk, benefits and limitations of genetic testing. (January 2019)
GECKO deep dive: A 9-page, comprehensive evidence-based resource for healthcare practitioners. Features a bottom line, red flags for a genomic assessment, associated cancer risk, benefits and limitations of genetic testing, references and more. (January 2019).
General Hereditary Cancer
Point of care tool: Red Flags (7) to identify those with risk of a Hereditary Cancer Syndrome most likely to benefit from a referral to genetics. *version français disponible* (updated July 2024)
Hereditary Renal Cell Carcinoma
Point of care tool: Outlines how to identify those patients most likely to benefit from referral to genetics for assessment of a hereditary renal cell cancer syndrome including brief summary of renal cell carcinoma syndromes. (January 2023)
